Learn more

TAIWANJ PHARMACEUTICALS CO LTD

Overview
  • Total Patents
    60
  • GoodIP Patent Rank
    25,637
  • Filing trend
    ⇧ 20.0%
About

TAIWANJ PHARMACEUTICALS CO LTD has a total of 60 patent applications. It increased the IP activity by 20.0%. Its first patent ever was published in 2003. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Taiwan. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are PROTEOTECH INC, PRODES SA and FIBROTECH THERAPEUTICS PTY LTD.

Patent filings per year

Chart showing TAIWANJ PHARMACEUTICALS CO LTDs patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Yang Syaulan S 32
#2 Wu Edwin Sc 23
#3 Jiang Yan-Feng 16
#4 Chiu Peter Js 16
#5 Liu Meng-Hsien 14
#6 Lee Kuang-Yuan 14
#7 Fan Yu-Shiou 13
#8 Lee Kuang Yuan 12
#9 Shih Ying-Chu 12
#10 Liu Meng Hsien 12

Latest patents

Publication Filing date Title
WO2020205455A1 Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same
TW202015684A Prodrugs of naltrexone, nalmefene and derivatives thereof
TW202019420A Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof
US2020352867A1 Pharmaceutical formulation for a solid dosage form of opioid receptor antagonists
US2020157088A1 Benzene fused heterocyclic compound and use thereof
CN111183130A Benzoheterocyclic derivatives and pharmaceutical compositions containing the same
US2018318290A1 Use of nalmefene in non-alcoholic steatohepatitis
WO2018156297A1 Sulfonamide or amide compounds, compositions and methods for the prophylaxis and/or treatment of autoimmune, inflammation or infection related disorders
EP3565556A1 Morphinan derivatives and compositions comprising the same for treating autoimmune, inflammation or infection related disorders
TW201813646A Use of NALMEFENE in non-alcoholic steatohepatitis
BR112018071705A2 prophylaxis method or treatment of nafld, nash or ash, use of a compound of formula (i), and compound of formula (i)
US2016287578A1 Toll-like receptor 4 antagonists and use in autoimmune liver diseases
EP2987788A1 Opioid and opioid-like compounds and uses thereof